Promising Preliminary Results Observed with Novel MK-4830 in Patients with Advanced Solid Tumours
MK-4830, an antibody targeting the myeloid-specific ILT4 receptor, shows promise in advanced solid tumours
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
Nivolumab Shows Promising Activity in Advanced Tumours with Rare Mutations
Data from first clinical study of nivolumab in patients with pathogenic edPOLE mutated MMR-proficient tumours
Pembrolizumab Delivers Clinical Benefit in Selected Histotypes of Rare Sarcoma
The best response in sarcoma patients treated with pembrolizumab was partial response in the AcSé Pembrolizumab study
Pralsetinib Shows Robust Activity in Patients with RET-Altered Medullary Thyroid Cancer
Pralsetinib had activity across all RET alterations and regardless of whether the RET mutation was somatic or germline
Novel Sotorasib Shows Promise in Non-Small Cell Lung Cancer
Sotorasib was active in patients with KRAS p.G12C mutation
Dual p16 and HPV Immunostaining Is Supported for Precise Classification of Oropharyngeal Cancer
Findings from the EPIC-OPC Study
Large Data Analysis Demonstrates Changes in Patient Outcomes and Treatment Strategies Over Time In Patients with Brain Metastasis
During long interval studied lung cancer remained the primary tumour source in patients newly diagnosed with brain metastasis
Short-term Preoperative Abemaciclib Shows a Significant Anti-Proliferative Effect in Early Breast Cancer
Abemaciclib treatment induces changes in the expression of several cell cycle biomarkers
TILs Indicate Outcome in Young Patients Not Receiving Systemic Adjuvant Treatment for TNBC
Tumour infiltrating lymphocyte levels may inform treatment decisions in women younger than 40 years with triple negative breast cancer
TERT Promoter Mutations May Not Be Indicative of Sensitivity To Temozolomide
TERT promoter mutation may not be linked to MGMT promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma
The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment Option in Advanced Clear Cell RCC
Nivolumab plus cabozantinib as first-line treatment for advanced clear cell renal cell carcinoma was consistently superior to sunitinib across all subgroups studied
Neoadjuvant Atezolizumab Is Safe in Resectable NSCLC
Findings from the PRINCEPS study